.Attributes Medication, Released online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antitoxin-- drug conjugate (ADC) tisotumab vedotin resulted in strengthened progression-free and also total survival, bring about FDA approval as well as a new treatment possibility for patients.